Union européenne -
français -
EMA (European Medicines Agency)
paxlovid
pfizer europe ma eeig - nirmatrelvir, ritonavir - covid-19 virus infection - paxlovid is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe covid 19.
Canada -
français -
Health Canada
paxlovid comprimé
pfizer canada ulc - ritonavir; nirmatrelvir - comprimé - 100mg; 150mg - ritonavir 100mg; nirmatrelvir 150mg
Suisse -
français -
Swissmedic (Swiss Agency for Therapeutic Products)
paxlovid comprimés pelliculés
pfizer ag - nirmatrelvirum, ritonavirum - comprimés pelliculés - a): nirmatrelvirum 150 mg, cellulosum microcristallinum, lactosum monohydricum 185 mg, carmellosum natricum conexum, silica colloidalis anhydrica, natrii stearylis fumaras, Überzug: hypromellosum, e 171, macrogolum 400, e 172 (rubrum), pro compresso obducto corresp. natrium 0.99 mg. b): ritonavirum 100 mg, copovidonum, silica colloidalis anhydrica, sorbitani lauras, calcii hydrogenophosphas, natrii stearylis fumaras, Überzug: hypromellosum, e 171, macrogolum 400, macrogolum 3350, hydroxypropylcellulosum, talcum, silica colloidalis anhydrica, polysorbatum 80, pro compresso obducto, natrium 0.388 mg. - behandlung von covid-19 - synthetika
Canada -
français -
Health Canada
paxlovid comprimé
pfizer canada ulc - ritonavir; nirmatrelvir - comprimé - 100mg; 150mg - ritonavir 100mg; nirmatrelvir 150mg